Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 5/20 | 0.49 |
| ▸ | GRIN3B | O60391 | 5/20 | 0.49 |
| ▸ | GRIN1 | Q05586 | 5/20 | 0.49 |
| ▸ | GRIN2A | Q12879 | 5/20 | 0.49 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.49 |
| ▸ | GRIN2C | Q14957 | 5/20 | 0.49 |
| ▸ | GRIN3A | Q8TCU5 | 5/20 | 0.49 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.49 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.49 |
| ▸ | SLC1A1 | P43005 | 3/20 | 0.49 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL43515 | 1.00 | GRIN2D (0.49) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL5980862 | 1.00 | GRIN2D (0.49) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL5605868 | 1.00 | GRIN2D (0.49) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL2652715 | 1.00 | GRIN2D (0.49) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL2651847 | 1.00 | GRIN2D (0.49) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL123134 | 1.00 | GRIN2D (0.49) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| Hydrochloric Acid SCHEMBL971796 | 0.98 | GRIN2D (0.47) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| Water SCHEMBL2651079 | 0.98 | GRIN2D (0.47) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| Water SCHEMBL29155398 | 0.98 | GRIN2D (0.47) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| Hydrochloric Acid SCHEMBL971795 | 0.98 | GRIN2D (0.47) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 597 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001915-A1 | METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST | RHYTHM PHARMACEUTICALS INC (US) | 2026-01-01 | — | — | US | claimed |
| US-20250361274-A1 | PEPTIDE AND PEPTIDE-CONTAINING AGENT | PEPTIDREAM INC. (JP) | 2025-11-27 | — | — | US | claimed |
| CN-120152725-A | Methods of treating obesity using MC4R agonists | 节奏制药公司 | 2025-06-13 | — | — | CN | claimed |
| EP-4554607-A2 | METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST | Rhythm Pharmaceuticals, Inc. (US) | 2025-05-21 | — | — | EP | claimed |
| EP-4541805-A1 | PEPTIDE AND PEPTIDE-CONTAINING AGENT | PeptiDream Inc. (JP) | 2025-04-23 | — | — | EP | claimed |
| US-20240368224-A1 | BICYCLIC PEPTIDYL PAN-RAS INHIBITORS | OHIO STATE INNOVATION FOUNDATION | 2024-11-07 | — | — | US | claimed |
| US-20240317803-A1 | BCL9 PEPTIDES AND VARIANTS THEREOF | WNTRX PHARMACEUTICALS INC. | 2024-09-26 | — | — | US | claimed |
| EP-4274838-B1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NK CELLS | BICYCLETX LTD (GB) | 2024-09-25 | — | — | EP | claimed |
| CN-118496313-A | Calcium sensitive receptor agonist compounds and uses thereof | 北京拓界生物医药科技有限公司 | 2024-08-16 | — | — | CN | claimed |
| EP-4388124-A1 | SELECTIVE MEASUREMENT OF HUMAN FACTOR VIII | Takeda Pharmaceutical Company Limited (JP) | 2024-06-26 | — | — | EP | claimed |
| WO-2005100385-A2 | COMPOUNDS THAT BLOCK THE C5A RECEPTOR AND THEIR USE IN THERAPY | ALLIGATOR BIOSCIENCE AB (PUBL) (SE) | 2005-10-27 | — | — | WO | claimed |
| EP-1586583-A2 | Compounds that block C5a complement receptor and their use in therapy | Alligator Bioscience AB (publ) (SE) | 2005-10-19 | — | — | EP | claimed |
| WO-2003006048-A1 | COMBINATION OF CHIPS (CHEMOTAXIS INHIBITING PROTEIN FROM STAPHYLOCOCCUS AUREUS)-BASED COMPOUNDS | JARI PHARMACEUTICALS B.V. (NL) | 2003-01-23 | — | — | WO | claimed |
| US-6495336-B1 | OLIGOPEPTIDE DERIVATIVES WHOSE C-TERMINAL AMINO ACID IS ARGININE WHICH IS LINKED TO THE REMAINDER OF AN ELECTROACTIVE ANILINE OR AMINOQUINILONE; SUBSTRATE FOR QUANTITATIVELY DETERMINING ENZYMES, ESPECIALLY THROMBIN, IN BLOOD | PENTAPHARM AG (CH) | 2002-12-17 | — | — | US | claimed |
| EP-1157029-A1 | OLIGOPEPTIDE DERIVATIVES FOR THE ELECTROCHEMICAL MEASUREMENT OF PROTEASE ACTIVITY | Pentapharm AG (CH) | 2001-11-28 | — | — | EP | claimed |
| WO-2000050446-A1 | OLIGOPEPTIDE DERIVATIVES FOR THE ELECTROCHEMICAL MEASUREMENT OF PROTEASE ACTIVITY | PENTAPHARM AG (CH) | 2000-08-31 | — | — | WO | claimed |
| EP-1025127-A1 | MSH-RECEPTOR SUBTYPE SELECTIVE CYCLIC PEPTIDES | Wapharm AB (SE) | 2000-08-09 | — | — | EP | claimed |
| EP-1023324-A1 | TRIVALENT THROMBIN INHIBITOR | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2000-08-02 | — | — | EP | claimed |
| WO-1999019356-A1 | TRIVALENT THROMBIN INHIBITOR | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 1999-04-22 | — | — | WO | claimed |
| WO-1998037097-A1 | MSH-RECEPTOR SUBTYPE SELECTIVE CYCLIC PEPTIDES | WAPHARM AB (SE) | 1998-08-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240317803-A1 | BCL9 PEPTIDES AND VARIANTS THEREOF | BCL9, BCL9L, BCL3 | GRIN2D 4702/4885GRIN3B 4728/4885GRIN1 4861/4885 |
| US-20260001915-A1 | METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST | MC4R, NPY4R, MC3R | GRIN2D 358/4885GRIN3B 162/4885GRIN1 555/4885 |
| US-20240368224-A1 | BICYCLIC PEPTIDYL PAN-RAS INHIBITORS | KRAS, HRAS, NRAS | GRIN2D 4825/4885GRIN3B 4347/4885GRIN1 4422/4885 |
| US-20250361274-A1 | PEPTIDE AND PEPTIDE-CONTAINING AGENT | BMP4, BMP1, BMPR2 | GRIN2D 3943/4885GRIN3B 3171/4885GRIN1 3937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.